Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Koelmeyer

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Lupus Science & Medicine|May 30, 2020
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosusRachel Koelmeyer, Hieu Tri Nim, Mandana Nikpour, et al.
Clinical & Translational Immunology|April 27, 2019
Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosusFabien B Vincent, Rangi Kandane-Rathnayake, Rachel Koelmeyer, et al.
Cancer|July 4, 2007
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alphaSusan Branford, Timothy Hughes, Alvin Milner, et al.
Frontiers in Immunology|August 6, 2019
Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus ErythematosusHieu T Nim, Kathryn Connelly, Fabien B Vincent, et al.
International Journal of Rheumatic Diseases|January 22, 2026
Prevalence, Treatment Patterns, and Outcomes Among Australian SLE Patients With Inadequately Controlled Disease ActivityAlberta Yik-Bun Hoi, Rachel Koelmeyer, Shereen Oon, et al.
Arthritis Care & Research|April 28, 2026
Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrualKevin Zhang, Eric F Morand, Sarah E Boyd, et al.
Arthritis Care & Research|July 9, 2019
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus ErythematosusAi Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, et al.
Frontiers in Immunology|June 23, 2018
Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus ErythematosusRachel Mende, Fabien B Vincent, Rangi Kandane-Rathnayake, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Lupus Science & Medicine|May 30, 2020
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosusRachel Koelmeyer, Hieu Tri Nim, Mandana Nikpour, et al.
Clinical & Translational Immunology|April 27, 2019
Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosusFabien B Vincent, Rangi Kandane-Rathnayake, Rachel Koelmeyer, et al.
Cancer|July 4, 2007
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alphaSusan Branford, Timothy Hughes, Alvin Milner, et al.
Frontiers in Immunology|August 6, 2019
Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus ErythematosusHieu T Nim, Kathryn Connelly, Fabien B Vincent, et al.
International Journal of Rheumatic Diseases|January 22, 2026
Prevalence, Treatment Patterns, and Outcomes Among Australian SLE Patients With Inadequately Controlled Disease ActivityAlberta Yik-Bun Hoi, Rachel Koelmeyer, Shereen Oon, et al.
Arthritis Care & Research|April 28, 2026
Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrualKevin Zhang, Eric F Morand, Sarah E Boyd, et al.
Arthritis Care & Research|July 9, 2019
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus ErythematosusAi Li Yeo, Rachel Koelmeyer, Rangi Kandane-Rathnayake, et al.
Frontiers in Immunology|June 23, 2018
Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus ErythematosusRachel Mende, Fabien B Vincent, Rangi Kandane-Rathnayake, et al.
Seminars in Arthritis and Rheumatism|September 26, 2022
Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysisTina Ko, Rachel Koelmeyer, Ning Li, et al.
Rheumatology (Oxford, England)|August 14, 2024
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosusKatie Liao, Ning Li, Julie Bonin, et al.
Pageof 4